AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 7848788
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy (Diltiazem 120 mg + Enalapril 10 mg)
Trial: 3057139
Drug: Antenatal steroids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antenatal steroids (20 mg dexamethasone)
Trial: 19926166
Drug: Routine antibiotics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Routine antibiotics
Trial: 796645
Drug: Ibuprofen (1200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibuprofen (1200 mg/day)
Trial: 31800551
Drug: Mega dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mega dose corticosteroid (30 mg/kg stat and 15 mg/kg every 6 hours for 3 days)
Trial: 28470106
Drug: Change in
RxNorm normalized name: monofluorophosphate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Change in neuropsychological test results during antipsychotic treatment
Trial: 24850465
Drug: Fish-based diet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fish-based diet (n-3 PUFAs ≧ 3.0 g/day)
Trial: 22702523
Drug: Oral fidaxomicin
RxNorm normalized name: Fidaxomicin
DrugBank: Fidaxomicin (DB08874)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oral fidaxomicin for 10 days
Trial: 3521518
Drug: Oral vancomycin
RxNorm normalized name: Vancomycin
DrugBank: Vancomycin (DB00512)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral vancomycin
Trial: 20034916
Drug: Neoadjuvant chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant chemotherapy with docetaxel combined with pirarubicin (TThp)
Trial: 20034916
Drug: Neoadjuvant chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant chemotherapy with docetaxel combined with epirubicin (TE)
Trial: 20034916
Drug: Neoadjuvant chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant chemotherapy (both regimens)
Trial: 15076172
Drug: Conventional diuretic
RxNorm normalized name: hydralazine hydrochloride / hydrochlorothiazide / reserpine Oral Tablet [Diuretic Ap-Es]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional diuretic and/or beta-blocker therapy
Trial: 10360293
Drug: Propranolol, 40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propranolol, 40 mg, administered 1 hour prior to surgery
Trial: 7731628
Drug: New therapeutic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: New therapeutic options for conservative treatment of vulvar lichen sclerosus
Trial: 466329
Drug: Conventional treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional treatment from qualified speech therapists
Trial: 466329
Drug: Treatment from
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment from non‐professional volunteers
Trial: 31829912
Drug: Concurrent ADT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concurrent ADT for 6 months starting simultaneously with RT
Trial: 28938962
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of oral anticoagulants and antiplatelet drugs
Trial: 25962329
Drug: Whole-body cooling
RxNorm normalized name: Insects (whole body), mite dermatophagoides farinae
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Whole-body cooling (intermittent immersion in 14°C water until rectal temperature reached 35.5°C or for a maximum of 170 min)
Trial: 23412808
Drug: Herbal/pharmaceutical supplements
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Herbal/pharmaceutical supplements
Trial: 8780630
Drug: CT-RT group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CT-RT group (cisplatin and vinblastine followed by radiation therapy)
Trial: 8780630
Drug: RT group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RT group (radiation therapy alone)
Trial: 23635728
Drug: Mefenamic acid
RxNorm normalized name: Mefenamic Acid
DrugBank: Mefenamic acid (DB00784)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mefenamic acid (500 mg, three times daily)
Trial: 3938014
Drug: RMSF cases
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RMSF cases (n=8, identified by direct fluorescent antibody technique)
Trial: 31628016
Drug: Tumour Treating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tumour Treating Fields (TTFields) at a frequency of 150 kHz delivered to the thorax in combination with intravenous pemetrexed (500 mg/m2 on day 1) and either cisplatin (75 mg/m2 on day 1) or carboplatin (AUC 5 on day 1) every 21 days for up to six cycles.
Trial: 31628016
Drug: Tumour Treating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tumour Treating Fields (TTFields) as maintenance treatment after chemotherapy.
Trial: 31628016
Drug: Chemotherapy (pemetrexed
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy (pemetrexed and platinum) without TTFields.
Trial: 1587408
Drug: Intravenous cerulein
RxNorm normalized name: Sambucus nigra subsp. cerulea fruit extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous cerulein at doses of 30-60 ng/kg.h
Trial: 1587408
Drug: 5 mg/kg.h
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg/kg.h loxiglumide with cerulein
Trial: 1587408
Drug: 5 mg/kg.h
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg/kg.h loxiglumide with a meal
Trial: 3884409
Drug: Piretanide tablet
RxNorm normalized name: piretanide
DrugBank: Piretanide (DB02925)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Piretanide tablet
Trial: 25074984
Drug: Testosterone-enanthate (TE)
RxNorm normalized name: Testosterone Enanthate
DrugBank: Testosterone enanthate (DB13944)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Testosterone-enanthate (TE) 125 mg/wk
Trial: 23095425
Drug: Oral methylphenidate
RxNorm normalized name: methylphenidate Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral methylphenidate stimulant medication
Trial: 20124887
Drug: Intensive insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intensive insulin therapy (targeting normoglycemia, between 4.4 and 6.1 mmol/L)
Trial: 20124887
Drug: Conventional insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Conventional insulin therapy (infusing insulin when blood glucose levels were >12 mmol/L and stopping at 10 mmol/L)
Trial: 17393164
Drug: Weekly paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Weekly paclitaxel at a dose of 100 mg/m2 followed by carboplatin AUC 2, administered in blocks of six cycles with treatment-free intervals.
Trial: 12469706
Drug: Hormone Replacement
RxNorm normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hormone Replacement Therapy (HRT) plus bisphosphonate
Trial: 12469706
Drug: HRT plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HRT plus selective estrogen receptor modulator
Trial: 12469706
Drug: Parathyroid hormone
RxNorm normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Parathyroid hormone (PTH) monotherapy
Trial: 12469706
Drug: HRT alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HRT alone or in combination with bisphosphonate or PTH
Trial: 10603129
Drug: Prolonged prednisolone
RxNorm normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Prolonged prednisolone treatment (16 weeks)
Trial: 10603129
Drug: Standard prednisolone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard prednisolone treatment (8 weeks)
Trial: 1770568
Drug: Continuous intravenous
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous intravenous pethidine infusion (100 mg.24 h‐1)
Trial: 1770568
Drug: Continuous epidural
RxNorm normalized name: ACCU-BLOC PERIFIX CONTINUOUS EPIDURAL ANESTHESIA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous epidural pethidine infusion (100 mg.24 h‐1)
Trial: 29176388
Drug: Citrulline Malate
RxNorm normalized name: CITRULLINE MALATE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Citrulline Malate (8 g)
Trial: 25825944
Drug: Continual uFSH
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continual uFSH (75 U, 3 times a week) and hCG (2000 U, twice a week)
Trial: 25825944
Drug: Sequential uFSH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential uFSH (75 U, 3 times a week every other 3 months) and hCG (2000 U, twice a week)
Trial: 24393576
Drug: Catheter ablation
RxNorm normalized name: CATHETER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Catheter ablation without antiarrhythmic drug therapy
Trial: 19265599
Drug: Recommended drugs
RxNorm normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recommended drugs
Trial: 19265599
Drug: Drugs only
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drugs only to be used in special circumstances
Trial: 19265599
Drug: Drugs which
RxNorm normalized name: Autologous CD34+ cells transduced with lentiviral vector which encodes for the aryl Sulfatase A complimentary deoxyribonucleic acid sequence
DrugBank: Atidarsagene autotemcel (DB17538)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drugs which should not be used in normal circumstances
Trial: 15185523
Drug: Urostim and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Urostim and antibiotic
Trial: 9563668
Drug: Beta-lactamase stable
RxNorm normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beta-lactamase stable antibiotic
Trial: 8206773
Drug: Nurse-delivered smoking
RxNorm normalized name: DELIVER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nurse-delivered smoking cessation intervention (three structured sessions during hospitalization, followed by weekly phone calls for 5 weeks after discharge)
Trial: 3207608
Drug: Chemotherapy (CT)
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy (CT) with or without radiotherapy (RT)
Trial: 3207608
Drug: Overall treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Overall treatment (CT, RT, or both)
Trial: 29459462
Drug: CABG+medical therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CABG+medical therapy (MED)
Trial: 18463831
Drug: Procalcitonin (PCT)
RxNorm normalized name: Procalcitonin
DrugBank: Procalcitonin (DB14812)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Procalcitonin (PCT) guided antibiotic therapy (duration: 5.9±1.7 days)
Trial: 18463831
Drug: Standardized duration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standardized duration of antibiotic therapy (control group, duration: 7.9±0.5 days)
Trial: 7437277
Drug: Paracetamol 1.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paracetamol 1.0 g
Trial: 2060559
Drug: Paracetamol 1.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paracetamol 1.0 g plus codeine 60 mg
Trial: 4028621
Drug: Aqueous methyl
RxNorm normalized name: methylal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aqueous methyl nicotinate (0, 0.1, 1.0, 10.0, and 100 mmol/L) with oral pretreatment of 25 mg doxepin hydrochloride
Trial: 4028621
Drug: Aqueous methyl
RxNorm normalized name: methylal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aqueous methyl nicotinate (0, 0.1, 1.0, 10.0, and 100 mmol/L) with oral pretreatment of 600 mg ibuprofen
Trial: 4028621
Drug: Aqueous methyl
RxNorm normalized name: methylal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aqueous methyl nicotinate (0, 0.1, 1.0, 10.0, and 100 mmol/L) with oral pretreatment of 50 mg indomethacin
Trial: 4028621
Drug: Aqueous methyl
RxNorm normalized name: methylal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aqueous methyl nicotinate (0, 0.1, 1.0, 10.0, and 100 mmol/L) with oral pretreatment of 975 mg aspirin
Trial: 4028621
Drug: Aqueous methyl
RxNorm normalized name: methylal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aqueous methyl nicotinate (0, 0.1, 1.0, 10.0, and 100 mmol/L) with oral pretreatment of lactose placebo
Trial: 29688502
Drug: Subcutaneous semaglutide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous semaglutide 0.5 mg once weekly
Trial: 29688502
Drug: Subcutaneous semaglutide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous semaglutide 1.0 mg once weekly
Trial: 20505674
Drug: Candesartan 8
RxNorm normalized name: candesartan 8 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Candesartan 8 mg once a day, titrated to 16 mg after 1 month
Trial: 20505674
Drug: Olmesartan 10
RxNorm normalized name: amlodipine-olmesartan 10 mg-20 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olmesartan 10 mg once a day, titrated to 20 mg after 1 month
Trial: 12627985
Drug: Lamotrigine 500
RxNorm normalized name: Lamotrigine
DrugBank: Lamotrigine (DB00555)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lamotrigine 500 mg/day
Trial: 8739928
Drug: Dextran infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dextran infusion (7 ml/kg)
Trial: 7952793
Drug: Inhaled salbutamol
RxNorm normalized name: salbutamol
DrugBank: Albuterol (DB01001)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Inhaled salbutamol 200 micrograms
Trial: 6867983
Drug: Inhaled salbutamol
RxNorm normalized name: salbutamol
DrugBank: Albuterol (DB01001)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Inhaled salbutamol 400 micrograms
Trial: 6867983
Drug: Inhaled salbutamol
RxNorm normalized name: salbutamol
DrugBank: Albuterol (DB01001)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Inhaled salbutamol 800 micrograms
Trial: 6867983
Drug: Inhaled salbutamol
RxNorm normalized name: salbutamol
DrugBank: Albuterol (DB01001)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Inhaled salbutamol 1600 micrograms
Trial: 18469572
Drug: Inhaled salbutamol
RxNorm normalized name: salbutamol
DrugBank: Albuterol (DB01001)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Inhaled salbutamol (all doses)
Trial: 30653490
Drug: AmBisome monotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AmBisome monotherapy (40 mg/kg)
Trial: 30653490
Drug: AmBisome (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AmBisome (30 mg/kg) with miltefosine (100 mg/day for 28 days)
Trial: 24694769
Drug: Triple antiplatelet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple antiplatelet therapy (TAT; DAT with cilostazol)
Trial: 29118299
Drug: Dual antiplatelet
RxNorm normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dual antiplatelet therapy (DAT; aspirin and clopidogrel)
Trial: 22480130
Drug: Fentanyl buccal
RxNorm normalized name: Fentanyl Buccal Film
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Fentanyl buccal tablet (FBT) in doses proportional to daily opioid doses (group P)
Trial: 22480130
Drug: Dose titration
RxNorm normalized name: Rebif Rebidose Titration Pack
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose titration of FBT starting with an initial dose of 100 µg (group T)
Trial: 16195824
Drug: 3.75 mg
RxNorm normalized name: zopiclone 3.75 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3.75 mg of GnRH agonist triptorelin acetate depot (Group I)
Trial: 16195824
Drug: 0.1 mg
RxNorm normalized name: biotin 0.1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.1 mg triptorelin acetate daily (Group II)
Trial: 11788184
Drug: Continuous estrogen-progestin
RxNorm normalized name: estrogens
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous estrogen-progestin therapy (Conjugated Equine Estrogens and Medroxyprogestin without interruption)
Trial: 11788184
Drug: Sequential regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential regimen (Conjugated Equine Estrogens over 25 days with Medroxyprogestin beyond the 14th day)
Trial: 8067712
Drug: Propionibacterium granulosum
RxNorm normalized name: Propionibacterium acnes
DrugBank: Propionibacterium acnes (DB19089)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propionibacterium granulosum KP-45, 10 mg administered intravenously between the seventh and third day prior to surgical treatment.
Trial: 8067712
Drug: Propionibacterium granulosum
RxNorm normalized name: Propionibacterium acnes
DrugBank: Propionibacterium acnes (DB19089)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propionibacterium granulosum KP-45 (treatment group)
Trial: 1092425
Drug: Nimorazole (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nimorazole (1 g orally at 12-hourly intervals for three doses)
Trial: 1092425
Drug: Metronidazole (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metronidazole (200 mg three times daily for 7 days)
Trial: 30375890
Drug: Flaxseed (15g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flaxseed (15g daily for 7 weeks)
Trial: 19650984
Drug: Clonidine transdermal
RxNorm normalized name: Clonidine Transdermal System
DrugBank: Clonidine (DB00575)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Clonidine transdermal patch
Trial: 28697832
Drug: Haloperidol tablets
RxNorm normalized name: Haloperidol Tablets
DrugBank: Haloperidol (DB00502)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Haloperidol tablets
Trial: 18692790
Drug: Combined hormone
RxNorm normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Combined hormone therapy (5 microg of ethinyl E(2) and 1 mg of norethindrone acetate)
Trial: 9286859
Drug: Antenatal betamethasone
RxNorm normalized name: Betamethasone
DrugBank: Betamethasone phosphate (DB14669)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Antenatal betamethasone (12 mg at a 12-h interval)
Trial: 12769404
Drug: Topical retinoids
RxNorm normalized name: tocopheryl retinoate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical retinoids
Trial: 2959308
Drug: Betahistine (H1-receptor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Betahistine (H1-receptor agonist)
Trial: 2958072
Drug: Histamine (combined
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Histamine (combined H1- and H2-receptor agonist)
Trial: 2959308
Drug: Impromidine (H2-receptor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Impromidine (H2-receptor agonist)
Trial: 30031389
Drug: Daily oral
RxNorm normalized name: GEMTESA 75 MG Once-Daily Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily oral dosages of 800 IU vitamin D3
Trial: 30031389
Drug: Single oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single oral dose of 300,000 IU vitamin D3
Trial: 25291578
Drug: 3.75 µg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3.75 µg of avian influenza Anhui vaccine with MF59 adjuvant
Trial: 25291578
Drug: 3.75 µg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3.75 µg of avian influenza Anhui vaccine without MF59 adjuvant
Trial: 25291578
Drug: 7.5 µg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7.5 µg of antigen with MF59 adjuvant
Trial: 25291578
Drug: 90 µg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 90 µg of unadjuvanted vaccine
Trial: 25291578
Drug: 7.5 µg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7.5 µg plus adjuvant
Trial: 22893166
Drug: COPE plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: COPE plus usual treatment (n = 55)
Trial: 22893166
Drug: Usual treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual treatment alone (control) (n = 48)
Trial: 20832701
Drug: Acetazolamide 85
RxNorm normalized name: Acetazolamide
DrugBank: Acetazolamide (DB00819)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Acetazolamide 85 mg
Trial: 16650180
Drug: Levocetirizine, 5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levocetirizine, 5 mg once daily
Trial: 12464713
Drug: Paroxetine up
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paroxetine up to 20 mg/day
Trial: 8859144
Drug: Breakfast at
RxNorm normalized name: rose bengal AT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Breakfast at school (200 ml of 3%-fat milk and 30 g of sugared cornflakes for 14 days)
Trial: 8218759
Drug: Continuous infusion
RxNorm normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous infusion of ranitidine (50 mg bolus + 0.125 mg.kg/h)
Trial: 8218759
Drug: Repeated boluses
RxNorm normalized name: eicosyl povidone (2 eicosyl branches-repeat)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Repeated boluses of ranitidine (50 mg every 6 h)
Trial: 22210797
Drug: Baseline period
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Baseline period (no treatment)
Trial: 3493738
Drug: cyclosporin A
RxNorm normalized name: Cyclosporin A
DrugBank: Cyclosporine (DB00091)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: cyclosporin A (CyA) 5 mg/kg body weight for six months
Trial: 17125809
Drug: Mass drug
RxNorm normalized name: Xenon, isotope of mass 129
DrugBank: Xenon Xe-129 (DB17386)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mass drug administration (MDA) programme against filariasis
Trial: 15235203
Drug: Conventional regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional regimen of intravenous fluid administration (Control)
Trial: 7024866
Drug: Ibuprofen (1600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibuprofen (1600 mg/day)
Trial: 3163538
Drug: Ibuprofen (1600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibuprofen (1600 mg/day) plus Meptazinol (400 mg/day)
Trial: 30446471
Drug: Water vapor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Water vapor thermal therapy (Rezūm procedure)